Petros Christopoulos, Klaus Kluck, Martina Kirchner, Heike Lüders, Julia Roeper, Roger-Fei Falkenstern-Ge, Marlen Szewczyk, Florian Sticht, Felix C Saalfeld, Claas Wesseler, Björn Hackanson, Sebastian Dintner, Martin Faehling, Jonas Kuon, Melanie Janning, Diego Kauffmann-Guerrero, Daniel Kazdal, Sylke Kurz, Florian Eichhorn, Farastuk Bozorgmehr, Rajiv Shah, Amanda Tufman, Martin Wermke, Sonja Loges, Wolfgang M Brueckl, Christian Schulz, Daniel Misch, Nikolaj Frost, Jens Kollmeier, Martin Reck, Frank Griesinger, Christian Grohé, Jin-Liern Hong, Huamao M Lin, Jan Budczies, Albrecht Stenzinger, Michael Thomas
BACKGROUND: EGFR exon20 insertions (ex20ins) are targeted by novel compounds in non-small-cell lung cancer (NSCLC). However, data about outcome under conventional therapies and the influence of molecular features are scarce. PATIENTS AND METHODS: We retrospectively analysed 118 patients with evaluation of radiologic response based on RECIST v1.1. TP53 status was available for 88 cases. RESULTS: Platinum doublets and chemoimmunotherapy showed similar response rates (20-25%), disease control rates (80%) and median progression-free survival (mPFS, ≈7 months), which were longer compared to monochemotherapy (9%, 59%, 4...
May 19, 2022: European Journal of Cancer